266 results
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
of Pombiliti + Opfolda All eligible clinical trial patients treated with commercial product or scheduled to be treated Majority of new commercial patients
8-K
EX-10.2
FOLD
Amicus Therapeutics Inc
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
Restrictions otherwise require or provide or the Holders holding a majority of the Registrable Securities otherwise agree. From and after the such date
8-K
EX-10.1
jaxisy0pxd s9msr4
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.2
wnv6i2
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
8-K
EX-99.1
0655t87ux1x1ak
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
EX-99.2
ftfo5b
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-10.1
36icw7reev8x2sj72vuj
12 May 23
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-99.2
ruti0aj e7tr5i
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
EX-10.1
p0cb pf53lzibm
28 Dec 22
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-99.1
xbc 27d2q8vz
16 Nov 22
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
7:01am
8-K
EX-99.2
z0teikvu04 k0hqnfy1
7 Nov 22
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
2:31pm
424B5
yfq728v4m7rb
7 Nov 22
Prospectus supplement for primary offering
7:11am
8-K
EX-99.2
9egc3ld v753ry3
7 Nov 22
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
w67jxxbs
14 Sep 22
Corporate Overview September 2022 At the Forefront of Therapies for Rare Diseases
7:00am